



Voyager Therapeutics to Present at Investor Conferences in September

08/28/18

CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:

- **Wells Fargo Healthcare Conference, Boston**
Date: Wednesday, September 5, 2018
Presentation Time: 8:30 a.m. EDT
- **HC Wainwright Global Investment Conference, New York City**
Date: Wednesday, September 5, 2018
Presentation Time: 5:00 p.m. EDT
- **Baird Global Healthcare Conference, New York City**
Date: Thursday, September 6, 2018
Presentation Time: 11:25 a.m. EDT
- **Morgan Stanley Global Healthcare Conference, New York City**
Date: Thursday, September 13, 2018
Presentation Time: 4:00 p.m. EDT

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager's website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager's pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson's disease, a monogenic form of ALS called SOD1, Huntington's disease, Friedreich's ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer's disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.

Investor Relations:

Matt Osborne

Vice President of Investor Relations & Corporate Communications

857-259-5353 ☐

mosborne@vygr.com

Media: ☐

Josie Butler

W20/Pure Communications, Inc.

910-239-5099 ☐

jbutler@w2ogroup.com



Voyager Therapeutics, Inc.